| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30076298 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30018918 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063743 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063744 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063745 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063746 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063747 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063748 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063749 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
| TVIS30063750 | HIV | ENSG00000113580.15 | protein_coding | NR3C1 | No | No | 2908 | E5KQF5 E5KQF6 F1D8N4 P04150 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NR3C1 |
|---|---|
| DrugBank ID | DB00180 |
| Drug Name | Flunisolide |
| Target ID | BE0000794 |
| UniProt ID | P04150 |
| Regulation Type | agonist |
| PubMed IDs | 2386110; 9563368; 15285788; 9523318; 11368283; 8466638; 11752352 |
| Citations | Hochhaus G, Moellmann HW: Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions. 1990 Jun;30(3-4):377-80.@@Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 2):S434-9.@@Valotis A, Hogger P: Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res. 2004 Jul 22;5:7.@@Hogger P, Erpenstein U, Rohdewald P, Sorg C: Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 1998 Feb;15(2):296-302.@@Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs. 2001;61(5):573-8.@@Philibert D, Bouchoux F, Cerede E, Corallo F, Allaire JM: [Pharmacologic study of the glucocorticoid activity of flunisolide compared with other steroids in the rat]. Allerg Immunol (Paris). 1993 Feb;25(2):77-81.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | 21-hydroxysteroids |
| SMILES | [H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO |
| Pathways | |
| PharmGKB | PA449661 |
| ChEMBL | CHEMBL1512 |
